Literature DB >> 3789473

[Application of a co-electrosyneresis reaction to the diagnosis and serological surveillance of candidiasis in a hospital milieu].

D Poulain, J Fruit, L Fournier, F Masson, E Dei-Cas, A Vernes.   

Abstract

We have previously described a co-immunofiltration reaction which identifies a specific precipitating system (SPCS) in sera from patients presenting systemic candidiasis. The SPCS is characterized by coalescence with an experimental serum directed against the germinative tubes of Candida albicans. The present study concerns our experience of the use of co-immunofiltration in routine hospital practice. Complete observations involving clinical, mycological and serologic data were selected in order to illustrate various possible developmental trends for SPCS during candidiasis. The SPCS usually develops early infections due to the yeast species most frequently implicated in hospital pathologies; an increase in its intensity reflects a developing infection or the start of therapy. The SPCS disappears slowly and gradually when infectious development is favorable, but its sudden disappearance represents an unfavorable prognosis correlated with detection of circulating antigens. Circulating antigens are also seen in severe cases of candidiasis in which the SPCS is not present. Indeed there is a certain complementarity between these two observations.

Entities:  

Mesh:

Year:  1986        PMID: 3789473

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  2 in total

1.  A monoclonal antibody to a cell wall component of Candida albicans.

Authors:  V Hopwood; D Poulain; B Fortier; G Evans; A Vernes
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Identification and specificity of a 38 kDa Loa loa antigenic fraction in sera from high-microfilaraemic Gabonese patients.

Authors:  A Walker-Deemin; A Ferrer; F Gauthier; M Kombila; D Richard-Lenoble
Journal:  Parasitol Res       Date:  2003-11-25       Impact factor: 2.289

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.